Evidence map›Paper›PMID 32290462›Full record

ArticleJournal of clinical medicine2020

Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients.

Laura Llinàs-Mallol, Dolores Redondo-Pachón, Dàlia Raïch-Regué, María José Pérez-Sáez, José Yélamos, Xavier Duran, Anna Faura, Miguel López-Botet, Julio Pascual, Marta Crespo

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Laura Llinàs-MallolDepartment of Nephrology; Hospital del Mar, 08003 Barcelona, Spain.ORCID 0000-0003-4696-3331
Dolores Redondo-PachónDepartment of Nephrology; Hospital del Mar, 08003 Barcelona, Spain.ORCID 0000-0002-0458-0052
Dàlia Raïch-ReguéDepartment of Nephrology; Hospital del Mar, 08003 Barcelona, Spain.ORCID 0000-0001-7656-5700
María José Pérez-SáezDepartment of Nephrology; Hospital del Mar, 08003 Barcelona, Spain.
José YélamosDepartment of Immunology, Hospital del Mar, 08003 Barcelona, Spain.
Xavier DuranMethodology & Biostatistics Support Unit, IMIM, 08003 Barcelona, Spain.
Anna FauraDepartment of Nephrology; Hospital del Mar, 08003 Barcelona, Spain.
Miguel López-BotetDepartment of Immunology, Hospital del Mar, 08003 Barcelona, Spain.ORCID 0000-0003-4882-065X
Julio PascualDepartment of Nephrology; Hospital del Mar, 08003 Barcelona, Spain.
Marta CrespoDepartment of Nephrology; Hospital del Mar, 08003 Barcelona, Spain.
Hospital Del Mar · ESMunicipal Institute for Medical Research · ESUniversitat Pompeu Fabra · ES

Funding

Fundació Catalana de Trasplantament Beca per a la recercaInstituto de Salud Carlos III PI10/01370Instituto de Salud Carlos III PI13/00598Instituto de Salud Carlos III PI16/00617Instituto de Salud Carlos III RD12/0021/0024Instituto de Salud Carlos III RD16/0009/0013Instituto de Salud Carlos III Sara Borrell Fellowship
6 · The paper itself

Abstract

Classical immunosuppression based on steroids, calcineurin inhibitors, and mycophenolate results in several unwanted effects and unsatisfactory long-term outcomes in kidney transplantation (KT). New immunosuppressors search for fewer adverse events and increased graft survival but may have a distinct impact on graft function and immunological biomarkers according to their mechanism of action. This prospective study evaluates the immunological effect of tacrolimus to serine/threonine protein kinase mechanistic target of rapamycin inhibitors (mTORi) conversion in 29 KT recipients compared with 16 controls maintained on tacrolimus. We evaluated renal function, human leukocyte antigen (HLA) antibodies and peripheral blood lymphocyte subsets at inclusion and at 3, 12, and 24 months later. Twenty immunophenotyped healthy subjects served as reference. Renal function remained stable in both groups with no significant change in proteinuria. Two patients in the mTORi group developed HLA donor-specific antibodies and none in the control group (7% vs. 0%,

Indexed as

donor-specific antibodyimmunophenotypekidney transplantationmTOR inhibitorsNK cellstransitional B cellsT regulatory cells

Identifiers

PMID32290462
PMCPMC7230655
OpenAlexW3015336400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.